Shots:

• The EMA’s CHMP issued a recommendation to use Paxlovid in adults with COVID-19 who do not require supplemental oxygen & are at high risk of progressing to sev. disease
• The recommendation is based on the P-II/III (EPIC-HR) study of Paxlovid in non-hospitalized adults with COVID-19 which showed an 89% reduction in risk of COVID-19-related hospitalization or death from any cause within 3 days of symptom & no deaths were observed while similar results were seen with those treated within 5 days of symptom
• The company initiates the rolling submission with the EMA for EU marketing authorization of PAXLOVID. If authorized, it will be recommended as an at-home treatment for high-risk patient

Ref: Pfizer | Image: The Wall Street Journal